FDI-6

Catalog No.S9689 Batch:S968901

Print

Technical Data

Formula

C19H11F4N3OS2
Molecular Weight 437.43 CAS No. 313380-27-7
Solubility (25°C)* In vitro DMSO 87 mg/mL (198.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.42mg/ml Taking the 1 mL working solution as an example, add 50 μL 8.3 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to make it clear. Volume up to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description FDI-6 (NCGC00099374) is an inhibitor of the Forkhead box protein M1 transcription factor (FOXM1) with IC50 of 22.5 μM.
Targets
FOXM1 [1]
(Cell-free assay)
22.5 μM
In vitro

FDI-6 (NCGC00099374) is characterized in depth and is shown to bind directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induces concomitant transcriptional down-regulation. Global transcript profiling of MCF-7 cells by RNA-seq shows that FDI-6 specifically down-regulates FOXM1-activated genes with FOXM1 occupancy confirmed by ChIP-seq.[1]
In vivo

Inhibiting FOXM1 with FDI-6 inhibits liver cancer cell growth in vivo.[2]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    MCF-7 cells

  • Concentrations

    20 μM, 40 μM

  • Incubation Time

    6 h

  • Method

    MCF-7 cells are grown in 15 cm2 dishes to 70% confluence prior to FDI-6 or DMSO control treatment for 6h. Cells are washed with PBS, cross-linked with 1% formaldehyde at RT for 10 min and quenched with 1/20 volume glycine (2.5 M). Cells are harvested by scraping into cold PBS containing protease inhibitors and cell pellets stored at −80 ℃.
Animal Study:

[2]
  • Animal Models

    4-week old male nude mice

  • Dosages

    25 mg/kg

  • Administration

    intratumoral injection

Selleck's FDI-6 has been cited by 3 publications

A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells [ Med Oncol, 2024, 41(8):188] PubMed: 38918225
Methionine regulates self-renewal, pluripotency, and cell death of GIC through cholesterol-rRNA axis [ BMC Cancer, 2022, 22(1):1351] PubMed: 36564758
The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer [ Cell Death Dis, 2021, 12(10):944] PubMed: 34650035

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.